Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

Key inclusion criteria: * Fully understand and voluntarily sign informed consent. 3-35years old. At least one legal guardian and/or Subjects to sign informed consent. * Clinically diagnosed as β-thalassemia major, phenotypes including β0β0, β+β+、β +β0, βEβ0 genotype. * Subjects with no affection with EBV, HIV, CMV, TP, HAV, HBV and HCV. * Subjects body condition eligible for autologous stem cell transplant. Key exclusion criteria: * Subjects acceptable for allogeneic hematopoietic stem cell transplantation and have an available fully matched related donor. * Active bacterial, viral, or fungal infection. * Treated with erythropoietin prior 3 months. * Immediate family member with any known hematological tumor. * Subjects with severe psychiatric disorders to be unable to cooperate. * Recently diagnosed as malaria. * History of complex autoimmune disease. * Persistent aspartate transaminase (AST), alanine transaminase (ALT), or total bilirubin value \>3 X the upper limit of normal (ULN). * Subjects with severe heart, lung and kidney diseases. * With serious iron overload, serum ferritin\>5000mg/ml. * Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician or Investigator. * Subjects who are receiving treatment from another clinical study, or have received another gene therapy. * Subjects or guardians had resisted the guidance of the attending doctor. * Subjects whom the investigators do not consider appropriate for participating in this clinical study